Previously, we reported the construction of HAC vectors containing the entire dystrophin genomic region (DYS-HAC) for gene therapy targeting Duchenne muscular dystrophy (DMD) (Kazuki et al. 2010). The gene discussed is DMD; the disease is Duchenne muscular dystrophy.